{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:28:23Z","timestamp":1787164103210,"version":"build-2736575974"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:00:00Z","timestamp":1783728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:00:00Z","timestamp":1783728000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Zhejiang Cancer Foundation of Scientific Research","award":["ZJCF-2025-1-YB-11"],"award-info":[{"award-number":["ZJCF-2025-1-YB-11"]}]},{"name":"Zhejiang Medical and Health Science and Technology Project","award":["2022KY637"],"award-info":[{"award-number":["2022KY637"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Apoptosis"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s10495-026-02388-x","type":"journal-article","created":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T13:54:56Z","timestamp":1783778096000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Axitinib promotes stemness and vasculogenic mimicry in triple-negative breast cancer by disrupting THBS1-CD47 axis-mediated endothelial-tumor cell communication"],"prefix":"10.1007","volume":"31","author":[{"given":"Lei","family":"Lei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanhuan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojing","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongguo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengyong","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangming","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingbin","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yabing","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7005-0842","authenticated-orcid":false,"given":"Xiaojia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6553-6824","authenticated-orcid":false,"given":"Xiying","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,11]]},"reference":[{"key":"2388_CR1","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41523-022-00468-0","volume":"8","author":"P Zagami","year":"2022","unstructured":"Zagami P, Carey LA (2022) Triple negative breast cancer: Pitfalls and progress. NPJ breast cancer 8:95","journal-title":"NPJ breast cancer"},{"key":"2388_CR2","doi-asserted-by":"publisher","first-page":"1607960","DOI":"10.3389\/fonc.2025.1607960","volume":"15","author":"J Sheng","year":"2025","unstructured":"Sheng J, Zong X (2025) Liquid biopsy in TNBC: significance in diagnostics, prediction, and treatment monitoring. Front Oncol 15:1607960","journal-title":"Front Oncol"},{"key":"2388_CR3","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.canlet.2020.10.016","volume":"497","author":"X Bai","year":"2021","unstructured":"Bai X, Ni J, Beretov J, Graham P, Li Y (2021) Triple-negative breast cancer therapeutic resistance: Where is the Achilles\u2019 heel? Cancer Lett 497:100\u2013111","journal-title":"Cancer Lett"},{"key":"2388_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23031665","author":"P Ferrari","year":"2022","unstructured":"Ferrari P, Scatena C, Ghilli M, Bargagna I, Lorenzini G, Nicolini A (2022) Molecular mechanisms, biomarkers and emerging therapies for chemotherapy resistant TNBC. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms23031665","journal-title":"Int J Mol Sci"},{"key":"2388_CR5","doi-asserted-by":"publisher","first-page":"1441667","DOI":"10.3389\/fimmu.2024.1441667","volume":"15","author":"Y Yang","year":"2024","unstructured":"Yang Y, Li H, Yang W, Shi Y (2024) Improving efficacy of TNBC immunotherapy: based on analysis and subtyping of immune microenvironment. Front Immunol 15:1441667","journal-title":"Front Immunol"},{"key":"2388_CR6","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1038\/s41568-024-00714-6","volume":"24","author":"MA Harris","year":"2024","unstructured":"Harris MA, Savas P, Virassamy B et al (2024) Towards targeting the breast cancer immune microenvironment. Nat Rev Cancer 24:554\u2013577","journal-title":"Nat Rev Cancer"},{"key":"2388_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.104683","volume":"153","author":"KGK Deepak","year":"2020","unstructured":"Deepak KGK, Vempati R, Nagaraju GP et al (2020) Tumor microenvironment: challenges and opportunities in targeting metastasis of triple negative breast cancer. Pharmacol Res 153:104683","journal-title":"Pharmacol Res"},{"key":"2388_CR8","doi-asserted-by":"publisher","first-page":"118013","DOI":"10.1016\/j.biopha.2025.118013","volume":"186","author":"BK Alemu","year":"2025","unstructured":"Alemu BK, Tommasi S, Hulin JA, Meyers J, Mangoni AA (2025) Current knowledge on the mechanisms underpinning vasculogenic mimicry in triple negative breast cancer and the emerging role of nitric oxide. Biomedicine & pharmacotherapy\u2009=\u2009Biomedecine & pharmacotherapie 186:118013","journal-title":"Biomedicine & pharmacotherapy\u2009=\u2009Biomedecine & pharmacotherapie"},{"key":"2388_CR9","doi-asserted-by":"crossref","unstructured":"Xu XY, Kalambhe DR, Yu Y, et al. (2025) Co-delivery of shikonin and JQ1 inhibits triple-negative breast tumor progression and lung metastasis through inhibition of epithelial-mesenchymal transition and vasculogenic mimicry. Acta pharmacologica Sinica.","DOI":"10.1038\/s41401-025-01605-8"},{"key":"2388_CR10","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1080\/15384047.2017.1294288","volume":"18","author":"H Sun","year":"2017","unstructured":"Sun H, Zhang D, Yao Z et al (2017) Anti-angiogenic treatment promotes triple-negative breast cancer invasion via vasculogenic mimicry. Cancer Biol Ther 18:205\u2013213","journal-title":"Cancer Biol Ther"},{"key":"2388_CR11","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12943-020-01288-1","volume":"20","author":"X Wei","year":"2021","unstructured":"Wei X, Chen Y, Jiang X et al (2021) Mechanisms of vasculogenic mimicry in hypoxic tumor microenvironments. Mol Cancer 20:7","journal-title":"Mol Cancer"},{"key":"2388_CR12","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13045-020-00858-6","volume":"13","author":"Q Luo","year":"2020","unstructured":"Luo Q, Wang J, Zhao W et al (2020) Vasculogenic mimicry in carcinogenesis and clinical applications. J Hematol Oncol 13:19","journal-title":"J Hematol Oncol"},{"key":"2388_CR13","doi-asserted-by":"publisher","first-page":"220","DOI":"10.3389\/fonc.2020.00220","volume":"10","author":"MA Andonegui-Elguera","year":"2020","unstructured":"Andonegui-Elguera MA, Alfaro-Mora Y, C\u00e1ceres-Guti\u00e9rrez R, Caro-S\u00e1nchez CHS, Herrera LA, D\u00edaz-Ch\u00e1vez J (2020) An overview of vasculogenic mimicry in breast cancer. Front Oncol 10:220","journal-title":"Front Oncol"},{"key":"2388_CR14","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.13814","volume":"58","author":"S Liu","year":"2025","unstructured":"Liu S, Kang M, Ren Y et al (2025) The interaction between vasculogenic mimicry and the immune system: mechanistic insights and dual exploration in cancer therapy. Cell Prolif 58:e13814","journal-title":"Cell Prolif"},{"key":"2388_CR15","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/978-1-0716-2403-6_11","volume":"2514","author":"S Imani","year":"2022","unstructured":"Imani S, Liu S, Maghsoudloo M, Wen Q (2022) Histochemical staining of vasculogenic mimicry. Methods Mol Biol (Clifton, NJ) 2514:107\u2013120","journal-title":"Methods Mol Biol (Clifton, NJ)"},{"key":"2388_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112791","volume":"42","author":"IG Cannell","year":"2023","unstructured":"Cannell IG, Sawicka K, Pearsall I et al (2023) FOXC2 promotes vasculogenic mimicry and resistance to anti-angiogenic therapy. Cell Rep 42:112791","journal-title":"Cell Rep"},{"key":"2388_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.1318","volume":"5","author":"F Pezzella","year":"2022","unstructured":"Pezzella F, Ribatti D (2022) Vascular co-option and vasculogenic mimicry mediate resistance to antiangiogenic strategies. Cancer reports (Hoboken, NJ) 5:e1318","journal-title":"Cancer reports (Hoboken, NJ)"},{"key":"2388_CR18","first-page":"5039","volume":"13","author":"T Murai","year":"2023","unstructured":"Murai T, Matsuda S (2023) Targeting the PI3K-Akt-mTOR signaling pathway involved in vasculogenic mimicry promoted by cancer stem cells. Am J Cancer Res 13:5039\u20135046","journal-title":"Am J Cancer Res"},{"key":"2388_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/ptr.70360","author":"N Zheng","year":"2026","unstructured":"Zheng N, Chen Y, Luo S et al (2026) Flavokawain A targets CXCR4-mediated vasculogenic mimicry to reverse hepatocellular carcinoma resistance to tyrosine kinase inhibitors. Phytother Res. https:\/\/doi.org\/10.1002\/ptr.70360","journal-title":"Phytother Res"},{"key":"2388_CR20","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.3390\/cells10071758","volume":"10","author":"G Morales-Guadarrama","year":"2021","unstructured":"Morales-Guadarrama G, Garc\u00eda-Becerra R, M\u00e9ndez-P\u00e9rez EA, Garc\u00eda-Quiroz J, Avila E, D\u00edaz L (2021) Vasculogenic mimicry in breast cancer: clinical relevance and drivers. Cells 10:1758","journal-title":"Cells"},{"key":"2388_CR21","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1530\/ERC-19-0054","volume":"27","author":"Y Mao","year":"2020","unstructured":"Mao Y, Zhu L, Huang Z et al (2020) Stem-like tumor cells involved in heterogeneous vasculogenesis in breast cancer. Endocr Relat Cancer 27:23\u201339","journal-title":"Endocr Relat Cancer"},{"key":"2388_CR22","doi-asserted-by":"publisher","first-page":"30502","DOI":"10.18632\/oncotarget.8461","volume":"8","author":"B Sun","year":"2017","unstructured":"Sun B, Zhang D, Zhao N, Zhao X (2017) Epithelial-to-endothelial transition and cancer stem cells: two cornerstones of vasculogenic mimicry in malignant tumors. Oncotarget 8:30502\u201330510","journal-title":"Oncotarget"},{"key":"2388_CR23","volume":"1880","author":"Y Li","year":"2025","unstructured":"Li Y, Liu X, Dong Y, Zhou Y (2025) Angiogenesis causes and vasculogenic mimicry formation in the context of cancer stem cells. Biochim Biophys Acta 1880:189323","journal-title":"Biochim Biophys Acta"},{"key":"2388_CR24","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.3390\/cells10051070","volume":"10","author":"F Li","year":"2021","unstructured":"Li F, Xu J, Liu S (2021) Cancer stem cells and neovascularization. Cells 10:1070","journal-title":"Cells"},{"key":"2388_CR25","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.3390\/cancers12082138","volume":"12","author":"M Rezaei","year":"2020","unstructured":"Rezaei M, Martins Cavaco AC, Stehling M et al (2020) Extracellular vesicle transfer from endothelial cells drives VE-cadherin expression in breast cancer cells, thereby causing heterotypic cell contacts. Cancers 12:2138","journal-title":"Cancers"},{"key":"2388_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.vph.2021.106873","volume":"140","author":"E Alf\u00ec","year":"2021","unstructured":"Alf\u00ec E, Thairi C, Femmin\u00f2 S et al (2021) Extracellular vesicles (EVs) in ischemic conditioning and angiogenesis: Focus on endothelial derived EVs. Vascul Pharmacol 140:106873","journal-title":"Vascul Pharmacol"},{"key":"2388_CR27","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s12964-022-00904-5","volume":"20","author":"J Gao","year":"2022","unstructured":"Gao J, Zhang X, Jiang L, Li Y, Zheng Q (2022) Tumor endothelial cell-derived extracellular vesicles contribute to tumor microenvironment remodeling. Cell Commun Signal 20:97","journal-title":"Cell Commun Signal"},{"key":"2388_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22094570","author":"S Kaur","year":"2021","unstructured":"Kaur S, Bronson SM, Pal-Nath D, Miller TW, Soto-Pantoja DR, Roberts DD (2021) Functions of thrombospondin-1 in the tumor microenvironment. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms22094570","journal-title":"Int J Mol Sci"},{"key":"2388_CR29","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s13046-018-0815-2","volume":"37","author":"M Xiao","year":"2018","unstructured":"Xiao M, Zhang J, Chen W, Chen W (2018) M1-like tumor-associated macrophages activated by exosome-transferred THBS1 promote malignant migration in oral squamous cell carcinoma. J Exp Clin Cancer Res 37:143","journal-title":"J Exp Clin Cancer Res"},{"key":"2388_CR30","doi-asserted-by":"publisher","first-page":"5534","DOI":"10.1038\/s41467-023-41095-y","volume":"14","author":"M Omatsu","year":"2023","unstructured":"Omatsu M, Nakanishi Y, Iwane K et al (2023) THBS1-producing tumor-infiltrating monocyte-like cells contribute to immunosuppression and metastasis in colorectal cancer. Nat Commun 14:5534","journal-title":"Nat Commun"},{"key":"2388_CR31","first-page":"291","volume":"24","author":"JS Isenberg","year":"2020","unstructured":"Isenberg JS, Roberts DD (2020) THBS1 (thrombospondin-1). Atlas Genet Cytogenet Oncol Haematol 24:291\u2013299","journal-title":"Atlas Genet Cytogenet Oncol Haematol"},{"key":"2388_CR32","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.niox.2009.05.005","volume":"21","author":"JS Isenberg","year":"2009","unstructured":"Isenberg JS, Shiva S, Gladwin M (2009) Thrombospondin-1-CD47 blockade and exogenous nitrite enhance ischemic tissue survival, blood flow and angiogenesis via coupled NO-cGMP pathway activation. Nitric Oxide 21:52\u201362","journal-title":"Nitric Oxide"},{"key":"2388_CR33","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.semcdb.2023.06.009","volume":"155","author":"E Longhi","year":"2024","unstructured":"Longhi E, Carminati L, Carlessi E, Belotti D, Taraboletti G (2024) Thrombospondin-1 in drug activity and tumor response to therapies. Semin Cell Dev Biol 155:45\u201351","journal-title":"Semin Cell Dev Biol"},{"key":"2388_CR34","doi-asserted-by":"publisher","first-page":"253","DOI":"10.2203\/dose-response.09-049.Reynolds","volume":"8","author":"AR Reynolds","year":"2010","unstructured":"Reynolds AR (2010) Potential relevance of bell-shaped and u-shaped dose-responses for the therapeutic targeting of angiogenesis in cancer. Dose Response 8:253\u2013284","journal-title":"Dose Response"},{"key":"2388_CR35","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1161\/ATVBAHA.122.318904","volume":"43","author":"B Singla","year":"2023","unstructured":"Singla B, Aithbathula RV, Pervaiz N et al (2023) CD47 activation by thrombospondin-1 in lymphatic endothelial cells suppresses lymphangiogenesis and promotes atherosclerosis. Arterioscler Thromb Vasc Biol 43:1234\u20131250","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2388_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.658547","volume":"11","author":"Y Li","year":"2021","unstructured":"Li Y, Li F, Bai X et al (2021) ITGA3 Is associated with immune cell infiltration and serves as a favorable prognostic biomarker for breast cancer. Front Oncol 11:658547","journal-title":"Front Oncol"},{"key":"2388_CR37","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/s12957-025-03840-z","volume":"23","author":"Y Mei","year":"2025","unstructured":"Mei Y, Zhao L, Zhou N (2025) SDC1 is a critical transmembrane proteoglycan in breast cancer. World J Surg Oncol 23:193","journal-title":"World J Surg Oncol"},{"key":"2388_CR38","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s13577-020-00362-6","volume":"33","author":"L Yu","year":"2020","unstructured":"Yu L, Xu H, Zhang S, Chen J, Yu Z (2020) SDC1 promotes cisplatin resistance in hepatic carcinoma cells via PI3K-AKT pathway. Hum Cell 33:721\u2013729","journal-title":"Hum Cell"},{"key":"2388_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104740","volume":"211","author":"R Xu","year":"2025","unstructured":"Xu R, Guo S, Song Q, Wang X, Li Q (2025) PD-1\/PD-L1 inhibitors combined with anti-angiogenic drugs for advanced triple-negative breast cancer: Synergistic mechanisms and research progress. Crit Rev Oncol Hematol 211:104740","journal-title":"Crit Rev Oncol Hematol"},{"key":"2388_CR40","doi-asserted-by":"publisher","first-page":"4413","DOI":"10.1038\/s41467-021-24703-7","volume":"12","author":"J Xu","year":"2021","unstructured":"Xu J, Yang X, Deng Q et al (2021) TEM8 marks neovasculogenic tumor-initiating cells in triple-negative breast cancer. Nat Commun 12:4413","journal-title":"Nat Commun"},{"key":"2388_CR41","doi-asserted-by":"publisher","first-page":"3226","DOI":"10.1016\/j.apsb.2025.04.006","volume":"15","author":"S Wu","year":"2025","unstructured":"Wu S, Tang Q, Fang W et al (2025) Targeting stem-property and vasculogenic mimicry for sensitizing paclitaxel therapy of triple-negative breast cancer by biomimetic codelivery. Acta pharmaceutica Sinica B 15:3226\u20133242","journal-title":"Acta pharmaceutica Sinica B"},{"key":"2388_CR42","doi-asserted-by":"publisher","DOI":"10.3390\/ijms262311289","author":"NA Tchurikov","year":"2025","unstructured":"Tchurikov NA, Klushevskaya ES, Lukicheva VN et al (2025) During the formation of vasculogenic mimicry by melanoma cells, the silencing of two sets of developmental genes is coupled either with an increase or a decrease in contacts with the nucleoli. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms262311289","journal-title":"Int J Mol Sci"},{"key":"2388_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115455","volume":"167","author":"J Huang","year":"2023","unstructured":"Huang J, Wang C, Hou Y et al (2023) Molecular mechanisms of thrombospondin-2 modulates tumor vasculogenic mimicry by PI3K\/AKT\/mTOR signaling pathway. Biomed Pharmacother 167:115455","journal-title":"Biomed Pharmacother"},{"key":"2388_CR44","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1016\/j.ajpath.2024.08.010","volume":"194","author":"J Li","year":"2024","unstructured":"Li J, Ding X, Yan W et al (2024) Tumor-derived immunoglobulin-like transcript 4 promotes postoperative relapse via inducing vasculogenic mimicry through MAPK\/ERK signaling in hepatocellular carcinoma. Am J Pathol 194:2398\u20132411","journal-title":"Am J Pathol"},{"key":"2388_CR45","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1080\/02688697.2021.1884648","volume":"38","author":"HM Witte","year":"2024","unstructured":"Witte HM, Riecke A, Steinestel K et al (2024) The addition of chloroquine and bevacizumab to standard radiochemotherapy for recurrent glioblastoma multiforme. Br J Neurosurg 38:404\u2013410","journal-title":"Br J Neurosurg"},{"key":"2388_CR46","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.canlet.2021.08.028","volume":"524","author":"M He","year":"2022","unstructured":"He M, Yang H, Shi H et al (2022) Sunitinib increases the cancer stem cells and vasculogenic mimicry formation via modulating the lncRNA-ECVSR\/ER\u03b2\/Hif2-\u03b1 signaling. Cancer Lett 524:15\u201328","journal-title":"Cancer Lett"},{"key":"2388_CR47","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.3390\/cancers14071639","volume":"14","author":"J Ding","year":"2022","unstructured":"Ding J, Cui XG, Chen HJ et al (2022) Targeting circDGKD intercepts TKI\u2019s effects on up-regulation of estrogen receptor \u03b2 and vasculogenic mimicry in renal cell carcinoma. Cancers 14:1639","journal-title":"Cancers"},{"key":"2388_CR48","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.21873\/anticanres.17045","volume":"44","author":"R Hujanen","year":"2024","unstructured":"Hujanen R, Salo T, Eklund KK, Salem A (2024) Ex vivo evaluation of antiangiogenic drugs in oral cancer: potential implications for targeting vasculogenic mimicry. Anticancer Res 44:2377\u20132392","journal-title":"Anticancer Res"},{"key":"2388_CR49","doi-asserted-by":"publisher","first-page":"5009","DOI":"10.1038\/s41467-018-07308-5","volume":"9","author":"T Xiang","year":"2018","unstructured":"Xiang T, Lin YX, Ma W et al (2018) Vasculogenic mimicry formation in EBV-associated epithelial malignancies. Nat Commun 9:5009","journal-title":"Nat Commun"},{"key":"2388_CR50","doi-asserted-by":"publisher","first-page":"13770","DOI":"10.3390\/ijms241813770","volume":"24","author":"G Morales-Guadarrama","year":"2023","unstructured":"Morales-Guadarrama G, M\u00e9ndez-P\u00e9rez EA, Garc\u00eda-Quiroz J et al (2023) The Inhibition of the FGFR\/PI3K\/Akt Axis by AZD4547 Disrupts the proangiogenic microenvironment and vasculogenic mimicry arising from the interplay between endothelial and triple-negative breast cancer cells. Int J Mol Sci 24:13770","journal-title":"Int J Mol Sci"},{"key":"2388_CR51","doi-asserted-by":"publisher","first-page":"584","DOI":"10.3389\/fcell.2020.00584","volume":"8","author":"C Montemagno","year":"2020","unstructured":"Montemagno C, Pag\u00e8s G (2020) Resistance to anti-angiogenic therapies: a mechanism depending on the time of exposure to the drugs. Front Cell Develop Biol 8:584","journal-title":"Front Cell Develop Biol"},{"key":"2388_CR52","doi-asserted-by":"publisher","first-page":"299","DOI":"10.20892\/j.issn.2095-3941.2018.0209","volume":"16","author":"H Sun","year":"2019","unstructured":"Sun H, Yao N, Cheng S et al (2019) Cancer stem-like cells directly participate in vasculogenic mimicry channels in triple-negative breast cancer. Cancer Biol Med 16:299\u2013311","journal-title":"Cancer Biol Med"},{"key":"2388_CR53","doi-asserted-by":"publisher","first-page":"326","DOI":"10.12688\/f1000research.11771.1","volume":"7","author":"S Ma","year":"2018","unstructured":"Ma S, Pradeep S, Hu W, Zhang D, Coleman R, Sood A (2018) The role of tumor microenvironment in resistance to anti-angiogenic therapy. F1000Research 7:326","journal-title":"F1000Research"},{"key":"2388_CR54","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/1476-4598-13-207","volume":"13","author":"D Zhang","year":"2014","unstructured":"Zhang D, Sun B, Zhao X et al (2014) Twist1 expression induced by sunitinib accelerates tumor cell vasculogenic mimicry by increasing the population of CD133+ cells in triple-negative breast cancer. Mol Cancer 13:207","journal-title":"Mol Cancer"},{"key":"2388_CR55","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.3390\/ijms25031782","volume":"25","author":"E Corbella","year":"2024","unstructured":"Corbella E, Fara C, Covarelli F et al (2024) THBS1 and THBS2 enhance the in vitro proliferation, adhesion, migration and invasion of intrahepatic cholangiocarcinoma cells. Int J Mol Sci 25:1782","journal-title":"Int J Mol Sci"},{"key":"2388_CR56","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s13048-025-01668-5","volume":"18","author":"H Liang","year":"2025","unstructured":"Liang H, Zhang S (2025) Thrombospondin-1 induces CD8(+) T cell exhaustion and immune suppression within the tumor microenvironment of ovarian cancer. J Ovar Res 18:99","journal-title":"J Ovar Res"},{"key":"2388_CR57","first-page":"828","volume":"35","author":"Q Huang","year":"2019","unstructured":"Huang Q, Huang Y, Li M, Zhang W (2019) The poor prognosis is correlated with the high expression of vascular endothelial growth factor (VEGF) and low expression of thrombospondin 1 (TSP-1) in patients with breast cancer. Xi bao yu fen zi mian yi xue za zhi\u2009=\u2009Chinese J Cell Mol Immunol 35:828\u2013831","journal-title":"Xi bao yu fen zi mian yi xue za zhi\u2009=\u2009Chinese J Cell Mol Immunol"},{"key":"2388_CR58","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0161007","volume":"11","author":"TY Weng","year":"2016","unstructured":"Weng TY, Wang CY, Hung YH, Chen WC, Chen YL, Lai MD (2016) Differential Expression Pattern of THBS1 and THBS2 in Lung Cancer: Clinical Outcome and a Systematic-Analysis of Microarray Databases. PLoS ONE 11:e0161007","journal-title":"PLoS ONE"},{"key":"2388_CR59","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1002\/jhbp.376","volume":"23","author":"H Teraoku","year":"2016","unstructured":"Teraoku H, Morine Y, Ikemoto T et al (2016) Role of thrombospondin-1 expression in colorectal liver metastasis and its molecular mechanism. J Hepatobiliary Pancreat Sci 23:565\u2013573","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"2388_CR60","doi-asserted-by":"publisher","first-page":"18809","DOI":"10.1038\/s41598-022-23500-6","volume":"12","author":"FH Ji","year":"2022","unstructured":"Ji FH, Qiu XG (2022) THBS1, a fatty acid-related metabolic gene, can promote the development of laryngeal cancer. Sci Rep 12:18809","journal-title":"Sci Rep"},{"key":"2388_CR61","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12943-019-0991-5","volume":"18","author":"L Mashouri","year":"2019","unstructured":"Mashouri L, Yousefi H, Aref AR, Ahadi AM, Molaei F, Alahari SK (2019) Exosomes: composition, biogenesis, and mechanisms in cancer metastasis and drug resistance. Mol Cancer 18:75","journal-title":"Mol Cancer"},{"key":"2388_CR62","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1038\/s41392-020-00359-5","volume":"5","author":"E Yang","year":"2020","unstructured":"Yang E, Wang X, Gong Z, Yu M, Wu H, Zhang D (2020) Exosome-mediated metabolic reprogramming: the emerging role in tumor microenvironment remodeling and its influence on cancer progression. Signal Transduct Target Ther 5:242","journal-title":"Signal Transduct Target Ther"},{"key":"2388_CR63","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s11010-023-04737-9","volume":"479","author":"S Lin","year":"2024","unstructured":"Lin S, Zhu B (2024) Exosome-transmitted FOSL1 from cancer-associated fibroblasts drives colorectal cancer stemness and chemo-resistance through transcriptionally activating ITGB4. Mol Cell Biochem 479:665\u2013677","journal-title":"Mol Cell Biochem"},{"key":"2388_CR64","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202100294RR","volume":"35","author":"B Li","year":"2021","unstructured":"Li B, Cao Y, Sun M, Feng H (2021) Expression, regulation, and function of exosome-derived miRNAs in cancer progression and therapy. FASEB J: Off Publ Fed America Soc Exp Biol 35:e21916","journal-title":"FASEB J: Off Publ Fed America Soc Exp Biol"},{"key":"2388_CR65","first-page":"12","volume":"37","author":"F Liao","year":"2022","unstructured":"Liao F, Liao Z, Zhang T et al (2022) ECFC-derived exosomal THBS1 mediates angiogenesis and osteogenesis in distraction osteogenesis via the PI3K\/AKT\/ERK pathway. J Orthop Trans 37:12\u201322","journal-title":"J Orthop Trans"},{"key":"2388_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2021.121185","volume":"279","author":"S Patwardhan","year":"2021","unstructured":"Patwardhan S, Mahadik P, Shetty O, Sen S (2021) ECM stiffness-tuned exosomes drive breast cancer motility through thrombospondin-1. Biomaterials 279:121185","journal-title":"Biomaterials"},{"key":"2388_CR67","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12974-025-03382-x","volume":"22","author":"C Liu","year":"2025","unstructured":"Liu C, Sui H, Li Z et al (2025) THBS1 in macrophage-derived exosomes exacerbates cerebral ischemia-reperfusion injury by inducing ferroptosis in endothelial cells. J Neuroinflammation 22:48","journal-title":"J Neuroinflammation"},{"key":"2388_CR68","volume":"1877","author":"HT Bian","year":"2022","unstructured":"Bian HT, Shen YW, Zhou YD et al (2022) CD47: Beyond an immune checkpoint in cancer treatment. Biochim Biophys Acta 1877:188771","journal-title":"Biochim Biophys Acta"},{"key":"2388_CR69","doi-asserted-by":"publisher","first-page":"4056","DOI":"10.7150\/thno.40860","volume":"10","author":"T Hu","year":"2020","unstructured":"Hu T, Liu H, Liang Z et al (2020) Tumor-intrinsic CD47 signal regulates glycolysis and promotes colorectal cancer cell growth and metastasis. Theranostics 10:4056\u20134072","journal-title":"Theranostics"},{"key":"2388_CR70","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1158\/0008-5472.CAN-19-2374","volume":"80","author":"E Sami","year":"2020","unstructured":"Sami E, Paul BT, Koziol JA, ElShamy WM (2020) The Immunosuppressive microenvironment in BRCA1-IRIS-overexpressing TNBC tumors is induced by bidirectional interaction with tumor-associated macrophages. Can Res 80:1102\u20131117","journal-title":"Can Res"},{"key":"2388_CR71","doi-asserted-by":"publisher","first-page":"10133","DOI":"10.18632\/oncotarget.7100","volume":"7","author":"S Kaur","year":"2016","unstructured":"Kaur S, Elkahloun AG, Singh SP et al (2016) A function-blocking CD47 antibody suppresses stem cell and EGF signaling in triple-negative breast cancer. Oncotarget 7:10133\u201310152","journal-title":"Oncotarget"},{"key":"2388_CR72","doi-asserted-by":"publisher","first-page":"4062","DOI":"10.3390\/ijms22084062","volume":"22","author":"A Kale","year":"2021","unstructured":"Kale A, Rogers NM, Ghimire K (2021) Thrombospondin-1 CD47 signalling: from mechanisms to medicine. Int J Mol Sci 22:4062","journal-title":"Int J Mol Sci"}],"container-title":["Apoptosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10495-026-02388-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10495-026-02388-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10495-026-02388-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:02:37Z","timestamp":1787162557000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10495-026-02388-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,11]]},"references-count":72,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["2388"],"URL":"https:\/\/doi.org\/10.1007\/s10495-026-02388-x","relation":{},"ISSN":["1360-8185","1573-675X"],"issn-type":[{"value":"1360-8185","type":"print"},{"value":"1573-675X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,11]]},"assertion":[{"value":"13 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The animal experiments were approved by the Laboratory Animal Ethics Committee of Zhejiang Cancer Hospital (Approval No. 2020\u201307-003). All procedures strictly followed the institutional guidelines for animal welfare and the ARRIVE guidelines. This study involving human tissues was approved by the Ethics Committee of Zhejiang Cancer Hospital (Approval No. IRB-2025-1270-IIT). All procedures were performed in accordance with the ethical standards of the institutional research committee.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"190"}}